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Abstract
Background: Studies of patients with paraneoplastic neurologic disorders (PND) have revealed that apoptotic tumor serves
as a potential potent trigger for the initiation of naturally occurring tumor immunity. The purpose of this study was to assess
the feasibility, safety, and immunogenicity of an apoptotic tumor-autologous dendritic cell (DC) vaccine.
Methods and Findings: We have modeled PND tumor immunity in a clinical trial in which apoptotic allogeneic prostate
tumor cells were used to generate an apoptotic tumor-autologous dendritic cell vaccine. Twenty-four prostate cancer
patients were immunized in a Phase I, randomized, single-blind, placebo-controlled study to assess the safety and
immunogenicity of this vaccine. Vaccinations were safe and well tolerated. Importantly, we also found that the vaccine was
immunogenic, inducing delayed type hypersensitivity (DTH) responses and CD4+ and CD8+ T cell proliferation, with no
effect on FoxP3+ regulatory T cells. A statistically significant increase in T cell proliferation responses to prostate tumor cells
in vitro (p=0.002), decrease in prostate specific antigen (PSA) slope (p=0.016), and a two-fold increase in PSA doubling time
(p=0.003) were identified when we compared data before and after vaccination.
Conclusions: An apoptotic cancer cell vaccine modeled on naturally occurring tumor immune responses in PND patients
provides a safe and immunogenic tumor vaccine. (ClinicalTrials.gov number NCT00289341).
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Introduction
Tumor immunity in patients with paraneoplastic neurologic
disorders (PND) have been studied with the hope of uncovering
principles that can be applied to the general population of cancer
patients[1,2]. These studies demonstrated tumor antigen-specific
CD8
+ T cells in the peripheral blood of PND patients[3,4], but
also generated a paradox. PND antigens are normally expressed in
the brain, and are ectopically expressed in tumors, but are not
expressed in dendritic cells (DCs) that are necessary to prime naı ¨ve
T cell responses.[5] Based on observations made with lupus
antigens[6], we hypothesized that apoptotic cells might serve as an
effective means of antigen transfer into DCs and presentation on
MHC I for the activation of CD8
+ T cells[7]. This proved to be
correct for both tumor[3] and viral antigens[8], and it is likely that
phagocytosis of apoptotic cells serve as a general means by which
the immune system surveys antigens throughout life. Insights from
studying natural tumor immunity in PND provide a compelling
base upon which to model clinical studies[2,9,10].
Several observations support the suggestion that apoptotic
tumor cells may serve as a potent source of antigen for stimulating
host immune responses in vivo. Theoretically, all potential tumor
antigens within an apoptotic tumor cell, and multiple epitopes
from each antigen, can be cross-presented by DCs, where
processed antigen may be placed on all (typically six) MHC I
alleles. This offers considerable advantages over peptide-pulsed
DC protocols, in which the investigator must have knowledge of
the tumor antigen and must choose specific MHC I-restricted
peptides for antigen stimulation. Antigen presentation from
apoptotic cells has been estimated to be 10,000–50,000 more
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DC[11,12]. Apoptotic material is processed by a natural pathway:
apoptotic cells are internalized by DC-restricted receptors,
including the avb5 integrin receptor[13], then processed within
DCs by distinct pathways[14]. These DCs then generate both
MHC I and MHC II peptide epitopes[13], leading to the
activation of both CD8
+ and CD4
+ T cells. Since the ability of
DCs cross-presenting apoptotic cells to activate effector CD8
+ T
cells requires signals from CD4 helper cells[15], the ability of
apoptotic material to be loaded on both MHC I and MHC II
molecules is of particular importance in considering its potential in
immunotherapy.
DCs presenting apoptotic tumor cells stimulate T cell responses
in animals and in vitro[16]. Clinically, several studies have used
killed tumor cells in vaccine trials, including glial[17–21],
prostate[22], melanoma[23], breast[24], ovarian[25] and pediatric
solid tumor cells[26] (reviewed in [9,16,27]). These studies have
not focused on apoptotic death per se, but rather have killed tumor
cells by various means (e.g. freeze-thawing, or large amounts of
UVB and gamma irradiation), leading to incompletely character-
ized mixtures of necrotic and apoptotic cell death. Interpretation
of these studies is complicated by controversy regarding the
immunogenic potency of different forms of dead cells[28].
Nonetheless, some trials have indicated the potential for
immunologic and clinical responses to autologous DC presenting
dead tumor cells[19,23]. Here we set out to more precisely test the
relationship between induction of PND-like tumor immune
responses and development of a clinical vaccine. We induced
apoptotic death of LNCaP prostate cancer cells, and allowed them
to be phagocytosed by autologous DCs generated from prostate
cancer patients’ peripheral blood monocytes; such DCs were
previously shown to stimulate both CD8
+ and CD4
+ T cells in
vitro[29], and in a B16 mouse melanoma model DCs cross-
presenting apoptotic tumor were effective in preventing tumor
growth (Blachere et al., unpublished data). Here we report the
safety and immunogenicity of DC/apoptotic LNCaP prostate
tumor cells in a controlled study of 24 prostate cancer patients.
Results
Study Population
Twenty-four consecutive eligible patients were vaccinated with
DC/LNCaP, together with control vaccinations. A total of 28.4–
78.9 million (average 50.3 million) DCs cross-presenting apoptotic
LNCaP tumor cells were given per patient, divided over 4 doses,
each 2 weeks apart (Figure 1). At the time of study entry, 11 of 12
patients in Arm 1 and 10 of 12 patients in Arm 2 had only
biochemical relapse with no other evidence of metastatic disease
(Table 1). The mean age of patients was 62.566.7 and 65.769.2
years and the mean Gleason score at study entry was 7.25 and
7.17 in Arms 1 and 2, respectively.
DC vaccine characteristics
DCs were cocultured with LNCaP or LNCaP-M1 cells that
were .90% apoptotic (Figure 2). All DC vaccine preparations
administered met criteria for viability and maturity (Table 2 and
Figure 2). DC function was monitored by allo-MLR; DCs
stimulated 2610
5 allogeneic T cells to incorporate $10
5 CPM
of
3H-thymidine on day 5 after an 18-hour
3H thymidine pulse
(data not shown).
Safety
The incidence of injection-site and systemic reactions to vaccine
are presented in Table 3. No vaccine related serious adverse events
were observed. Only 1 toxicity was significantly different between
the placebo and vaccine groups in the single blind phase of the
study: grade 1 or 2 injections site reactions that occurred in 11 of
12 patients in the vaccine group (p,0.001), attributable to vaccine
(but not placebo) generating DTH-like responses. There was no
symptomatic evidence of autoimmune disease in any patient,
including vasculitis, thyroiditis, colitis, neurologic disease, endo-
crinopathy or cardiomyopathy.
Immune response
All patients who received the DC/keyhole limpet hemocyanin
(KLH) vaccine had a positive DTH response to KLH. None of the
24 patients had a response to LNCaP lysate at baseline (week 0).
All 24 patients were given LNCaP lysate as part of DTH panels at
weeks 3, 5, 7, and 9. Sixteen of 24 patients (67%) had a DTH
response to LNCaP lysate in at least 1 of these 4 time points, with
the highest proportion of patients (54.2%) responding to LNCaP
lysate at 2 weeks after the last booster (week 9). Responses were
maintained in 9 of 13 patients (69%) at 22 weeks after the last
booster (week 29, Figure 3). The responses to LNCaP lysate were
statistically significant at all time points with a 95% confidence
interval. Normal saline, given as a control, was negative at all time
points in all patients.
A
3H thymidine proliferation assay was used to assess the
reactivity of T cells to KLH protein and to prostate tumor cells
(either those used in vaccination (LNCaP) or to another prostate
tumor cell line (PC3)). Negative control antigens included
autologous monocytes and an irrelevant cell line (3T3). 3T3
infected with influenza was used as positive control. T cells were
collected at week 0 (pre-vaccine) leukapheresis and week 13 (post-
vaccine) leukapheresis (Figure 1). To be valid, each individual
proliferation assay must have had a detectable influenza response
pre- and post-vaccine. Two of 24 patients had no detectable
influenza response and thus were excluded from analysis. The 22
evaluable patients, considered as a group, had no statistically
significant difference in T cell response to influenza, pre- versus
post-vaccine (p=0.310, data not shown). There was a statistically
significant T cell response to KLH post-vaccine vs pre-vaccine
(p=0.008), as well as to apoptotic LNCaP (p=0.017) and
apoptotic PC3 tumor cells (p=0.011) (Figure 4a). There were no
statistically significant differences in pre- vs post-vaccine T cell
responses to antigen presenting cells (APCs) alone (p=0.160), to
control antigens, 3T3 (p=0.070) or autologous monocytes
(p=0.156) (Table 4, Figure 4a and data not shown).
Based on the DTH data (Figure 3) and the
3H thymidine
proliferation data (Figure 4a), we calculated and ranked a DTH
index and a proliferation index to determine if there was an
association between the two. A positive correlation was found
(0.55 using the Spearman rank correlation test (p=0.008)),
indicating that patients who had positive DTH responses to
LNCaP lysate also tended to have T cell proliferation responses to
apoptotic LNCaP cells in vitro.
The proliferation response was also assessed by CFSE dye
dilution assay[30]. In 5 of 6 patients, a CD8+ T cell response
specific for prostate antigens was observed (Figure 4b and data not
shown). We confirmed that all six patients tested also had a CD4+
T cell response to prostate antigens.
We considered the possibility that the increased T cell
proliferation response post vaccination could relate to a decline
in regulatory T cells in circulation. To determine the percent of
CD4+ T cells that are T regulatory cells in pre- and post-
vaccinated blood samples, PBMCs were stained and assessed for
Foxp3 expression (Figure 5). No difference (p=0.924) was found
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PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12367Figure 1. Study Design (CONSORT Diagram). Patients were screened and randomized into 1 of 2 arms, each with 12 patients. Patients in both
arms were blind during the vaccine/placebo phases until Week 8. Patients in Arm 1 continued into the post-vaccine phase while patients in Arm 2
crossed over into the vaccine phase before entering post-vaccine phase.
doi:10.1371/journal.pone.0012367.g001
An Apoptotic Cancer Vaccine
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12367Table 1. Patient characteristics.
Pt Age Previous Treatments Clinical Status Gleason Score PSA at Study Entry
1 55 Leuprolide Acetate, Bicalutamide, Nilutamide CM/HR 8 0.69
2 80 RRP, Leuprolide Acetate, Bicalutamide BCR/HR 7 2.71
3 65 RRP, Salvage RT BCR 7 0.79
4 58 RRP BCR 6 0.49
5 64 RRP BCR 7 0.59
6 75 RRP CM 9 0.57
7 81 RT BCR 6 8.66
8 54 RRP, Salvage RT BCR 6 0.46
9 60 RRP, IL-2 and J-591 Ab Study, Testosterone Gel/ Leuprolide or Goserelin
Acetate/Docetaxel Study
BCR 7 7.56
10 57 Brachytherapy, Salvage RRP BCR 7 6.38
11 56 RRP, Salvage RT, Leuprolide Acetate, Bicalutamide BCR/HR 8 5.24
12 69 RRP, Salvage RT, Goserelin Acetate BCR/HR 7 0.86
13 63 RRP, Salvage, RT, Testosterone Gel/Leuprolide or Goserelin Acetate/
Docetaxel Study
BCR/HR 8 0.48
14 53 RRP, Salvage RT, Leuprolide Acetate LR/HR 8 0.94
15 57 RRP, Salvage RT, Leuprolide Acetate, Bicalutamide BCR 9 0.29
16 64 RRP BCR 7 15.27
17 68 RT, Testosterone Gel/Leuprolide or Goserelin Acetate/Docetaxel Study BCR 8 4.61
18 74 RRP BCR 6 40.25
19 67 RRP, Salvage RT BCR 7 5.02
20 63 RRP, Leuprolide Acetate, Bicalutamide BCR 7 2.15
21 59 RRP, Salvage RT BCR 7 0.62
22 70 RRP, Salvage RT BCR 7 1.75
23 55 RRP, Salvage RT BCR 7 0.44
24 68 RRP, Salvage RT BCR 7 1.27
Previous Treatments: RRP=Radical Retropubic Prostatectomy, RT=Radiation Therapy. Clinical Status: CM=Clinical Metastasis, HR=Hormone Refractory,
BCR=Biochemical Relapse, LR=Local Recurrence.
doi:10.1371/journal.pone.0012367.t001
Figure 2. Preparation of Vaccine. UV irradiation (+UV) specifically induced apoptosis in LNCaP cells as indicated by 96% Caspatag+ TOPRO+
staining 38 hours post UV. DC cocultured with apoptotic LNCaP cells (Vaccine) are mature, with .96% CD83 positive cells. Data shown is
representative of all 24 vaccines prepared.
doi:10.1371/journal.pone.0012367.g002
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Vaccine Groups % CD14 + Median (Interquartile Range) % CD83 + Median (Interquartile Range) % PI + Median (Interquartile Range)
DC/LNCaP 0.13 (0.83) 86.94 (8.86) 4.14 (5.87)
DC/LNCaP-M1 0.09 (0.48) 87.82 (6.86) 4.37 (4.69)
DC/KLH 0.09 (0.41) 96.19 (3.59) 1.25 (1.72)
DCs alone 0.17 (0.45) 96.41 (4.94) 1.52 (1.94)
Vaccine groups were prepared from patient monocytes as described. DCs were assessed for maturation by staining for expression of surface markers, CD14 and CD83,
and for viability using PI stain. Cells were assessed by flow cytometry on Day 8 prior to vaccine release. All vaccine groups administered met release criteria.
doi:10.1371/journal.pone.0012367.t002
Table 3. Adverse events.
Single Blind Unblinded
Arm 2 Placebo
Phase
Arm 1 Vaccine
Phase
Arm 2 Vaccine
Phase
Arm 1 and 2 Post-
Vaccine Phase
Total number of Adverse Events in each phase 80 120 90 76
No. Pts with at least 1 AE No. of pts (Total No. of pts) 12 (12) 12 (12) 12 (12) 22 (24)
RELATED TO VACCINE:
Adverse Events No. of events (No. of pts)
injection site reaction 2 (2) 22 (11) 29 (12) 0
injection site reaction (grade 2) 0 4 (2) 0 0
Serious Adverse Events No. of events (No. of pts) 0000
NOT RELATED TO VACCINE:
Frequently Occurring Adverse Events (occurring $5 times in study) No. of events (No. of pts)
albumin, serum, low 0 1 (1) 4 (3) 0
albumin, urine, high 2 (1) 3 (3) 0 3 (3)
ALT, serum, high 3 (3) 4 (2) 0 2 (2)
ALT, serum, high (grade 2) 0 0 1 (1) 0
ANA, high 1 (1) 1 (1) 3 (3) 4 (4)
BUN, serum, high 1 (1) 4 (3) 2 (2) 1 (1)
chloride, serum, high 4 (4) 1 (1) 0 2 (2)
CO2, serum, low 4 (4) 3 (2) 2 (2) 1 (1)
creatinine, serum, high 1 (1) 3 (2) 2 (2) 2 (2)
diarrhea/loose stools 1 (1) 5 (3) 0 0
edema, lower extremities 2 (2) 0 3 (1) 1 (1)
eosinophils, high 3 (3) 1 (1) 1 (1) 1 (1)
fatigue 5 (5) 6 (5) 5 (4) 0
glucose, serum, high, non-fasting 5 (5) 6 (6) 2 (1) 7 (6)
ketones, urine, high 2 (2) 1 (1) 1 (1) 3 (3)
potassium, serum, high 3 (3) 0 6 (5) 1 (1)
potassium, serum, high (grade 2) 1 (1) 0 0 0
rash 2 (2) 2 (1) 0 3 (2)
URI 3 (3) 3 (3) 1 (1) 0
Serious Adverse Events No. of Events (No. of pts) 01 ( 1 ) 03 ( 1 )
Hospitalization: Cardioversion for atrial fibrillation 0 1 (1) 0 0
Hospitalization: Urinary retention 0 0 0 1 (1)
Elective Hospitalization: Cholecystectomy 0 0 0 1 (1)
Elective Hospitalization: Inguinal hernia repair 0 0 0 1 (1)
Study visits during the placebo and vaccine phases are identical. Placebo injections consisted of vaccine vehicle only. All adverse events are Grade 1 unless otherwise
specified. There were no vaccine related serious adverse events. The only statistically significant adverse event was the number of patients having injection site
reactions between Arm 1 vaccine phase and Arm 2 pre-vaccine placebo phase (p=0.001, Fisher’s exact test). All other adverse events listed are not statistically
significant (p$0.2 in all cases, Fisher’s exact test) between Arm 1 vaccine phase and Arm 2 pre-vaccine placebo phase.
doi:10.1371/journal.pone.0012367.t003
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cells from 15 patients (Table 4).
PSA response
The prostate specific antigen doubling time (PSADT) was
calculated for each patient during each phase of study. The
median doubling time during the pre-vaccine phase was 4.5
months, and this increased to 5.4 and 8.9 months during the
vaccine and post-vaccine phases respectively. There were
statistically significant differences in PSADT between the pre-
and post-vaccine phases (p=0.003) and between the vaccine and
post-vaccine phases (p,0.001) but not between the pre-vaccine
and vaccine phases (p=0.915).
We also compared the slope of the PSA rise between the 3 study
phases. Eighteen of 23 (78%) evaluable patients had a decrease in
PSA slope between the pre- and post-vaccine phases. When
considering all 23 patients, there was a statistically significant
decrease in the PSA slope between the pre-vaccine and post-
vaccine phases of 20.093/month (p=0.016, Figure 6 and
Table 5). There was no statistical difference in PSA slope between
the pre-vaccine and vaccine phases (20.018/month, p=0.681) or
the vaccine and post-vaccine phases (20.075/month, p=0.098).
We evaluated whether this PSA slope change might result from the
development of serum anti-PSA antibodies. Pre- and post-vaccine
serum was assessed by measuring serum antibody reactivity to
purified PSA protein on Western blot, using PSA monoclonal
antibodies as a positive control. We found no evidence for
antibody reactivity to PSA (data not shown). Nonetheless, we
cannot rule out that antibodies are not detectable due to antigen/
antibody complexes being formed and that these somehow aided
in clearing PSA from the serum.
We then stratified the study population with two more fixed
effects on a mixed model and conducted a likelihood ratio test; the
patients that had a DTH response to LNCaP lysate had a
significantly different PSA slope change when compared to those
that had no DTH response to LNCAP lysate (p=0.004). Sixteen
of 24 patients had DTH responses to LNCaP in at least one time
point. This group of patients had a statistically significant change
in PSA slope between the pre-vaccine and post-vaccine phases
(20.105/month, p=0.020, Table 6). Eight of 24 patients had no
response to LNCaP lysate at any time point, and these patients
had no statistically significant change in slope between the pre-and
post-vaccine phases (20.033/month, p=0.631). When we strat-
ified the study population into 2 groups based on PSA value at
study entry, the likelihood ratio test indicated a significantly
different PSA slope change between these two groups (p,0.001).
With the mixed model, we found that those who had a PSA
$1 ng/ml at study entry (15 patients) had a significant PSA slope
change between pre- to post-vaccine phase (20.099/month,
p=0.031, Table 6) while the patient subgroup that had a PSA
,1 ng/ml at study entry (8 patients) did not (20.078/month,
p=0.279). Taken together, these data demonstrate that the study
patients taken as a group had a significant reduction in the rate of
rise of PSA after vaccination, and that this effect was particularly
evident in those with immunologic response and more readily
measurable disease.
Discussion
Patients with PND develop effective tumor suppression of
common cancer types[2] that are likely to be triggered by immune
recognition of ectopic expression of neuronal proteins by those
cancers. To trigger such immune responses, we hypothesized and
demonstrated that apoptotic tumor serves as a potent source of
antigen for presentation by APCs[7,29]. The focus of this study
was to evaluate the safety and immunogenicity of mimicking this
means of triggering tumor immunity by using prostate cancer
patients’ DCs cross-presenting apoptotic tumor cells as a cancer
vaccine.
Despite the conceptual link between the development of
apoptotic cells as a vaccine and tumor immunity in PND, we
Figure 3. DTH Responses. Vaccine induced DTH response to LNCaP cell lysates injected intradermally were measured at the indicated times. Week
1 was baseline, at which time no patients had DTH responses (data not shown). DTH responses were considered positive at $5 mm erythema read at
48 hours after placement. Bars indicate the number of patients with positive responses at each time point. Error bars represent 95% confidence
intervals. Dotted line represents trend of percentage of patients with positive responses at each time point. Statistically significant positive DTH
responses to LNCaP cell lysate appeared at Week 3 (first time point after baseline) and responses were still present in 9 of 13 patients (69%) at 22
weeks after the last booster dose (Week 29).
doi:10.1371/journal.pone.0012367.g003
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disease in our patients. We did note small ANA elevations post
vaccine in 5 patients (titer of 1:160 in one patient, #1:80 in four
patients) which resolved over time in 4/5 patients. However, we
also noted that of 7 patients with detectable ANA levels pre-
vaccination, 5 became lower after vaccination. Statistical analysis
of ANA changes pre versus post vaccine/placebo in Arm 1 versus
Arm 2 revealed no significant differences (Fisher’s exact test), and
we conclude that ANA changes were not clinically meaningful;
moreover, such transient responses have commonly been seen in
Figure 4. T cell proliferation response in vitro. Comparison of pre- and post-vaccine bulk T cell responses to prostate antigen. a. Apoptotic
tumor cells (LNCaP and PC3, or an irrelevant cell line (3T3)) or KLH protein were co-cultured with patient peripheral blood monocytes and syngeneic
bulk T cells obtained from patients pre- or post-vaccination. Monocytes without exogenous antigen (No Ag) or apoptotic 3T3 cells (Ctrl Ag), served as
negative controls. Proliferation was assessed on day 5 after an 18-hour
3H thymidine pulse. Data is presented for 22 of 24 patients. The difference in
proliferation (post- minus pre-vaccine) for each antigen group is shown in box plots. Values reported are average counts per minute (CPM) of
triplicate wells. The median difference for each antigen group is shown by the line in the box. Each patient who is an outlier is indicated by a unique
symbol. Statistically significant differences in pre-vaccine vs. post-vaccine T cell proliferative responses were found for KLH (p=0.008), LNCaP
(p=0.017) and PC3 (p=0.011). b. Bulk T cells obtained post-vaccination were stained with CFSE and cultured with DCs cross-presenting prostate
antigens, LNCaP and PC3, or an irrelevant cell line (293 cells, Ctrl Ag). Cell proliferation on day 5, assessed by CFSE dye dilution, is shown on the x-axis
and CD8 expression is shown on the y-axis. Percentages shown represent CD8+ cells that have divided within the bulk T cell population. Four of five
additional patients tested showed similar CD8+ responses; data shown are for patient #15.
doi:10.1371/journal.pone.0012367.g004
An Apoptotic Cancer Vaccine
PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12367DC based vaccines[26,31,32]. One reason that we chose prostate
cancer as an initial tumor for study using this vaccine approach is
that these tumors are rarely associated with PND. Despite the
safety of the vaccine here, caution is warranted in extending this
approach to patients harboring tumors known to be associated
with PND (for example gynecologic tumors expressing the cdr2 or
Nova antigens and small cell lung cancers expressing the Hu
antigen)[1,2].
Our dendritic cell/apoptotic tumor vaccine was immunogenic.
Sixty-seven percent of patients developed DTH responses to
LNCaP antigens. Furthermore, these DTH responses were
positively correlated with post-vaccine bulk T cell proliferation
responses. This high level of immunogenicity was similar to that
reported in other studies of peptide-pulsed or tumor cell associated
DC vaccines. Importantly, these responses included CD8+ T cell
responses to prostate tumor cells (Figure 4b). This is significant, as
a critical determinant of successful tumor vaccines is likely to be
induction of CD8+ T cell responses[33]. The ability to detect such
responses here is consistent with the observation that cross-
presentation of apoptotic cells are able to stimulate naı ¨ve and
memory CD8+ T cell responses to tumor cells[3] or to virally
infected cells[8] ex vivo. Due to the nature of the disease, autologous
tumor cells were not available for testing T cell responses.
However, both the CD4 and CD8 proliferation responses were
detected to prostate tumor cell lines, despite the high background
responses seen in T cells post vaccination (Figure 4a). Such
background responses have been seen before in DC-based
vaccines and are of uncertain etiology[34], and may be reflected
in transient increases in ANA seen in some patients. It is likely that
patients had variable immune responses to tumor vaccination,
either resulting from intrinsic differences in immune repertoire, or
from actions of the tumor itself to modify patient immune
responses[35].
Significantly, we found that PSA slopes decreased and PSADT
increased after vaccination in our patient population as a whole
(p=0.016). We hypothesized that if this correlation was related to
the immunogenicity of the vaccine, PSA changes should be present
in the subset of patients showing immunogenic response to vaccine
but not in those who do not. In fact, patients who had DTH
responses to LNCaP after vaccination had significant decreases in
PSA slope (p=0.020), compared to patients who did not have
DTH responses (p=0.631). Taken together, our data suggests that
the changes seen in PSA slope represent an immune response to
patient tumor cells in vivo.
Although variable immunologic and clinical responses have
been reported to vaccines using dead tumor cells as a source of
antigen, these studies have not focused on using pure, well-defined
populations of apoptotic tumor cells. We used UV-B irradiation to
induce apoptotic (not necrotic) death in .90% of the prostate cell
line used for the vaccine; nonetheless, our side-effect profile was
very low, similar to other tumor vaccines. Most other studies have
used gamma irradiation or freeze-thawing, generating variable
Table 4. Confidence intervals for T cell proliferation assay and
Foxp3+ cell analysis.
Group: p-value 95% CI
No Ag 0.160 (21703.275, 9649.413)
KLH 0.008* (4681.672, 27308.539)
LNCaP 0.017* (3759.725, 34618.214)
PC3 0.011* (5835.155, 38744.036)
3T3 0.070 (2862.319, 20294.713)
Foxp3+ cells 0.160 (20.978, 0.893)
95% confidence intervals and p-values for T cell proliferation response (
3H
thymidine incorporation assay) and %Foxp3+ cells (FACS analysis) comparing
cells collected pre-vaccine and post-vaccine using the paired t-test.
doi:10.1371/journal.pone.0012367.t004
Figure 5. Foxp3 expression pre- and post-vaccination. a. FACS profile of Foxp3 expression in pre- and post-vaccinated peripheral blood gated
on CD4+ T cells. A representative patient (#13) is shown. b. Box plots of the percent Foxp3+ cells (gated on CD4+ T cells) pre and post-vaccination in
15 representative patients, including those across the whole range of proliferative responses and changes in PSA slope. The median is shown by the
+. Outliers are indicated by N. No difference in pre-vaccine vs. post-vaccine T cell expression of Foxp3 (p=0.924) was observed.
doi:10.1371/journal.pone.0012367.g005
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differences in immunogenic potential[28].
Taken together, the results presented in this study provide initial
safety and immunogenicity data for a vaccine mimicking what we
believe is a critical trigger for naturally occurring effective tumor
immune responses seen in PND patients. These responses
correlate with a clinically relevant response to patient tumor, as
assessed by highly statistically significant effects on PSA slope and
doubling time. These observations suggest that this vaccination
approach warrants further exploration as a safe and potent means
of triggering tumor immune response in the general population of
cancer patients. Future vaccine modifications to be considered are
the addition of immune adjuvants during vaccine preparation ex
vivo or in conjunction with vaccine administration in vivo[9,36],
or the use of autologous tumor as a source of apoptotic antigen. In
addition, a safe means of vaccinating against prostate (or other)
cancers may serve in a synergistic manner with other immune-
stimulating agents, such as CTLA4-Ig, which are showing promise
in combined immunotherapies in prostate[37] and other can-
cers[38].
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Patients and Study Design
Ethics Statement. The study was approved by The
Rockefeller University Institutional Review Board (RDA-0466)
and the FDA (IND 10710). Written consent was obtained from all
patients. No de novo cell lines were generated in this study.
Figure 6. Change in PSA slope pre- to post-vaccine. Graph of the average log2 (PSA) slope per study phase (solid line); for comparison, an
extrapolation of the pre-vaccine average log2 (PSA) slope is shown (dotted line). Based on the linear spline model, the average change in PSA slope of
23 patients from pre- to post-vaccine phases is 20.093/month (p=0.016). One patient’s PSA values were not included in the analysis as his pre-
vaccine values were affected by other treatment near the start of study participation. Three other patients started other treatment either during or
after vaccination; PSA values obtained after this point were not included in the analysis.
doi:10.1371/journal.pone.0012367.g006
Table 5. Confidence intervals for PSA slopes.
PSA Slopes by Study Phases: p-value 95% CI
Pre- vs Post 0.016 (20.1694, 20.0166)
Pre- vs Vaccine 0.681 (20.1044, 0.0682)
Vaccine vs Post 0.098 (20.1613, 0.0134)
95% confidence intervals and p-values for PSA slopes comparing pre- vs
vaccine, vaccine vs post-vaccine, and pre- vs post-vaccine phases from the
linear mixed model.
doi:10.1371/journal.pone.0012367.t005
Table 6. Confidence intervals for PSA slopes upon
stratification.
Stratified by: p-value 95% CI
Whole group 0.016 (20.1694, 20.0166)
Response by DTH
to LNCaP lysate
Non-
Responders
0.631 (20.1682, 0.1022)
Responders 0.020 (20.1932, 20.0168)
PSA at start of study ,1 ng/ml 0.279 (0.2191, 0.0631)
$1 ng/ml 0.031 (20.1872, 20.0108)
95% confidence intervals and p-values for PSA slopes comparing pre- vs
vaccine, upon stratification by DTH response or no response to LNCaP lysate or
upon stratification by PSA ,1 ng/ml or 1 ng/ml at start of study.
doi:10.1371/journal.pone.0012367.t006
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University in New York; twenty-four patients aged 53 to 81 were
enrolled between November 2003 and February 2006. All authors
vouch for the completeness and accuracy of the data and its
analysis and participated in writing the article.
Twenty-four patients were randomly assigned to one of two
arms for the purpose of assessing vaccine safety, our primary
endpoint (Figure 1). All patients were blinded. Twelve patients
assigned to Arm 1 received vaccine followed by 3 vaccine boosts at
2-week intervals, for a total of four injections over eight weeks, and
were unblinded after the last booster. Twelve patients assigned to
Arm 2 received placebo (vehicle (5% DMSO in saline)) for each of
four injections, were unblinded, crossed over to the vaccine phase,
and received vaccine followed by 3 boosts at 2-week intervals.
After the last booster, patients in both groups were followed for up
to 22 weeks. All time points in both arms up to and including the
day of the first vaccination with DC vaccine were considered pre-
vaccine phase. All time points from the first booster through the
first follow up visit after the final vaccination (week 9) was
considered vaccine phase. All remaining time points in the study
were considered to be post-vaccine phase. Safety data was
compared between the 2 arms of the study, while immune and
PSA data were assessed by comparisons made between pre- and
post-vaccine phases in all 24 patients.
Patient Selection and Vaccination. Patients were eligible to
participate if they provided informed consent, had biopsy proven
prostate cancer and progressive disease: PSA documented to be
rising on 3 occasions, either despite castrate testosterone levels
(below 50 ng/dl) or despite definitive local therapy (prostatectomy,
radiation, etc.). Exclusion criteria included prior biologic therapy
with dendritic cells, autoimmune disease, or significant major
organ disease.
DC vaccines were given together with DTH panels and patients
were closely observed for one hour. Patients returned to clinic at
48 hours, at which time they were examined clinically and their
DTH responses were read. Vaccines were administered at a cell
dose ranging from 2210610
6 DCs/vaccination, given subcuta-
neously in the inner aspect of the upper arm, approximately 6–
8 cm from the axillary lymph nodes. Patients received one priming
and three biweekly booster vaccinations. During the first two
injections, patients also received 2210610
6 DC/KLH.
Vaccine
Vaccine was manufactured in a BSL-2 facility maintained and
independently audited to meet Good Tissue Practice specifica-
tions. To prepare autologous DCs, peripheral blood mononuclear
cells (PBMCs) were obtained by leukapheresis, adhered to
endotoxin free tissue-culture dishes (Falcon), and differentiated in
vitro to immature DCs over six days in RPMI-1640 supplemented
with 1% autologous plasma, GM-CSF (180 ng/ml; Bayer
HealthCare Pharmaceuticals) and IL-4 (10 mg/ml; R&D Systems)
as described[29,39]. LNCaP prostate tumor cells were obtained
from the American Type Cell Culture and a master cell bank was
made and screened by BioReliance Corporation (Rockville, MD)
to rule out contamination or adventitious agents. LNCaP cells
from the master stock (frozen in Aim V media (Invitrogen) plus
BSE-free fetal bovine serum (20% FBS; HyClone) and 5% DMSO
(Edward Life Sciences)) were expanded in Aim V media/1% FBS,
and cells were treated with UV-B irradiation such that .90% of
cells underwent apoptotic death (Caspatag positive, as de-
scribed[29]). Immature DCs and apoptotic LNCaP were co-
cultured at a ratio of 1:1 for 36–48 hours in the presence of PGE2
(20 mM; Sigma) and TNF-a (150 ng/ml; R&D Systems) to
mature DCs as described[40]. DCs pulsed with KLH (2.5 mg/ml,
biosyn) provided a positive control for DC function. All patients
were also immunized with 2210610
6 DCs cross-presenting
apoptotic LNCaP producing the M1 antigen as a potential
positive control (DC/LNCaP-M1), but only four patients were
HLA A2.1
+ and tetramer analysis did not show boosted M1
responses post vaccination in these patients (data not shown). The
quality and viability of the vaccine was monitored by flow
cytometry; to pass release criteria the HLA-DR (DC) cell fraction
had to be .70% CD83+, ,15% CD14+ and ,20% Propidium
Iodide (PI) + (Serologicals). All antibodies were purchased from
BD Pharmingen. Sterility was tested by gram stain, by culture for
bacterial and fungal contamination (BacT/ALERT, Biomereux),
and by DNA fluorochrome for mycoplasma (Bionique Testing
Laboratories, Inc.). The LAL method (Associates of Cape Cod)
was used to test for endotoxin. The final product was divided into
4 equal aliquots, each containing 2210610
6 DCs each. The first
aliquot was given as a ‘‘fresh’’ dose; all other aliquots were frozen
and thawed prior to administration.
Clinical and Immunomonitoring
Clinical Monitoring. Patients were monitored at each study
visit by history, physical examination, and by laboratory
evaluations including CBC, chemistries, and urinalysis, for any
adverse effects. The National Cancer Institute Common Toxicity
Criteria version 3 was used to grade toxicities. Patients were also
asked to maintain a diary of local injection site reactions and
systemic adverse events for one week following each vaccination.
To assess for clinical response, PSA levels were measured in the
serum using MSA Bayer Immuno I or IEA Tosoh Nexia assays at
each study visit. The PSA slope was calculated for each phase of
the study (pre-vaccine, vaccine, and post-vaccine phases) using a
linear mixed model with two knots representing the change in
slope in each phase of the study. In addition, for each phase of
study for each patient, a PSA doubling time (PSADT) was
calculated using the formula: 1 divided by the slope log2 PSA
derived from this linear spline model.
Immunomonitoring. A DTH panel was placed intra-
dermally at weeks 1 (vaccine), 3 (Boost #1), 5 (Boost #2), 7
(Boost #3), 9, 17 and 29 to assess for T cell responses. The panel
included lysate of 10
5 LNCaP cells (in 0.1 ml normal saline),
0.05 mg KLH, candida or tetanus toxoid (whichever the patient
had responses to at baseline, as positive control), and saline (as
negative control). Responses were considered positive if erythema
was equal to or greater than 5 mm at 48 hours post implantation.
We evaluated immunogenicity outcomes against apoptotic
LNCaP and PC3 (another prostate cancer tumor cell line) by
3H
thymidine or CFSE proliferation assays as described[29] with the
following modifications. In the
3H thymidine assay, autologous
monocytes (CD14+ cells) were used as APCs. 3T3 cells, an
irrelevant cell line, were used as the negative control antigen and
influenza infected (strain A/P/R8) 3T3 cells were used as a
positive control for both pre-vaccine and post-vaccine T cell
responses. 3T3 cells were obtained from the American Type Cell
Culture. In the CFSE assay, DCs cross-presenting prostate tumor
antigens or 293 cells (irrelevant cell line used as negative control
antigen) were used as APCs and cultured with T cells stained with
CFSE (Vibrant CFDA SE Cell Tracer Kit, Invitrogen). On day 5,
T cells were stained with anti-CD8 conjugated antibody (Becton
Dickinson) and analyzed using FlowJo software. All cell lines were
UV-B irradiated to induce apoptotic death three hours prior to co-
culture with APCs[29].
To assess for correlations between patients who had a DTH
response to LNCaP lysate and those who had T cell proliferation
responses to apoptotic LNCaP in vitro, patients were ranked by a
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3H thymidine) proliferation index. The
DTH index was calculated as the number of positive DTH
responses to LNCaP lysate divided by the total number of DTH
time points for each patient. The T cell proliferation index was
calculated as the post-vaccine LNCaP response (CPM) minus 2
standard deviations, divided by post-vaccine 3T3 response (CPM)
plus 2 standard deviations.
FACS staining of regulatory T cells was done by surface staining
with anti-CD4-FITC (Becton Dickinson) followed by intracellular
staining with anti-Foxp3-APC (eBioscience, clone PCH101) per
manufacturers instructions. For analysis, PBMCs were gated on
CD4+ T cells and the percentage of Foxp3+ cells was determined
(FlowJo).
Statistical Analysis
The protocol called for 12 patients to be recruited to each of two
arms, which would have 90% power to detect an increase in
cumulative serious adverse events (SAEs) from 5% in the placebo
group to 50% in the vaccine group at the 10% level. All adverse
events were analyzed using Fisher’s exact test to compare placebo
and vaccine phase. Significance of DTH responses to LNCaP cell
lysate was determined by the exact binomial test with 95%
confidence intervals. To analyze pre- to post- T cell proliferation
data (per antigen) for study subjects as a group, a two-sampled
paired t-test was used with 95% confidence intervals. The
Spearman rank correlation test was used to determine if those
that had DTH responses to LNCaP lysate also had T cell
proliferation responses to apoptotic LNCaP in vitro. The paired t-
test was used to compare the percentage of pre- vs post-vaccine
Foxp3+ cells in PBMCs with 95% confidence intervals. In all of
the above tests, the differences or correlation were deemed
statistically significant if the p-value was less than 0.05.
To model the evolution of PSA (in log-scale) during the three
study phases (pre-vaccine, vaccine, and post-vaccine phases), a
mixed linear spline model was used. Two knots (one at the start of
the vaccine phase and the other at the start of the post-vaccine
phase) were used to directly quantify the differences in slopes
between each phase. To account for the heterogeneous treatment
effect and the repeated measures structure, random effects are
incorporated into the model. For the general model, random
effects for the intercept, slope and the first knot were considered.
To determine if there was any difference in PSA slopes between
those that did have an immunologic response (DTH responders to
LNCaP lysate) and those that did not (DTH non-responders to
LNCaP lysate), a second model, stratified by these response
indicators (with separate knots for the two groups), was fitted and
the likelihood ratio test was conducted. Similarly, a third model
was fitted, this time, stratified by PSA at study start of ,1 ng/ml
or $1 ng/ml. The models with stratification were then compared
to the general model. All models were fitted and hypotheses were
tested using the lme package from R (www.R-project.org). The
Wilcoxon matched-paired signed rank test was used to determine
statistical significance of the difference in PSADT between phases
(www.fon.hum.uva.nl/service/statistics/signed_rank_test.html). A
PSADT can be a positive number as a result of rising PSA levels or
a negative number as a result of declining PSA levels. For the
purpose of statistical analysis, negative PSADT (indicating
declining PSAs) were replaced with 9999 months to represent an
infinitely long doubling time so that they rank higher than any
value for which doubling time was a positive number. Differences
were deemed significant if the p-value was less than 0.05.
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